One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism

David A Bushinsky, Glenn M Chertow, Sunfa Cheng, Hongjie Deng, Nelson Kopyt, Kevin J Martin, Anjay Rastogi, Pablo Ureña-Torres, Marc Vervloet, Geoffrey A Block, David A Bushinsky, Glenn M Chertow, Sunfa Cheng, Hongjie Deng, Nelson Kopyt, Kevin J Martin, Anjay Rastogi, Pablo Ureña-Torres, Marc Vervloet, Geoffrey A Block

Abstract

Background: Secondary hyperparathyroidism (sHPT), a common complication of chronic kidney disease, is characterized by elevated serum parathyroid hormone (PTH). Etelcalcetide is an intravenous calcimimetic that increases sensitivity of the calcium-sensing receptor to calcium and decreases PTH secretion. This open-label extension (OLE) trial evaluated the long-term effects of etelcalcetide for sHPT treatment in patients receiving hemodialysis.

Methods: This 52-week, multicenter, single-arm OLE enrolled patients from three parent trials: two randomized, double-blind, placebo-controlled trials and one open-label, single-arm, 'switch' study from cinacalcet to etelcalcetide. The primary endpoint was to investigate the nature, frequency, severity and relation to treatment of all adverse events (AEs) reported throughout the trial. Secondary endpoints included the proportion of patients with >30% reduction from baseline in PTH and the percentage change from baseline in PTH, albumin-corrected calcium (Ca), phosphate (P) and the calcium-phosphate product (Ca × P).ClinicalTrials.gov identifier: NCT01785875; Amgen study: 20120231.

Results: Overall, 89.8% of the patients experienced one or more treatment-emergent AE. The most common were decreased blood Ca (43.3%), diarrhea (10.8%), vomiting (10.4%) and nausea (9.6%); symptomatic hypocalcemia occurred in 3.7% of the patients. Approximately 68% of patients achieved >30% reduction in PTH, and ∼56% achieved PTH ≤300 pg/mL. Mean percent changes from baseline ranged from -25.4% to -26.1% for PTH, -8.3% to -9.1% for Ca, -3.6% to -4.1% for P and -12.0% to -12.6% for Ca × P.

Conclusions: Etelcalcetide effectively lowered PTH and its effect was sustained, while no new safety concerns emerged over a 1-year treatment period.

Keywords: chronic kidney disease; etelcalcetide; open-label extension; safety, secondary hyperparathyroidism.

© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.

Figures

FIGURE 1
FIGURE 1
Patient disposition. aTwo of the trials were randomized, double-blind, placebo-controlled trials conducted in 1023 patients [22]; the other trial was an open-label, single-arm, ‘switch’ from cinacalcet to etelcalcetide in 158 patients [23]. bSixteen patients from one site withdrew consent on 20 or 21 November 2014, subsequent to the investigator’s decisions to withdraw from the trial. Additionally, three patients from the same site had missing end-of-study data.
FIGURE 2
FIGURE 2
Proportion of patients receiving each dose level of etelcalcetide (mg/session) at selected visits. aOne patient received 17.5 mg of etelcalcetide in Week 26, although the maximum dose per protocol was 15 mg.
FIGURE 3
FIGURE 3
Proportion of patients with low Ca values during the trial for the current OLE study (black) versus the active treatment arm of the placebo-controlled trials [22] (gray). Ca, albumin-corrected calcium.
FIGURE 4
FIGURE 4
Mean (SE) predialysis PTH (A), Ca (B) and P (C) concentrations over time. BL, baseline; Ca, albumin-corrected calcium; P, phosphate.
FIGURE 5
FIGURE 5
Concomitant medication use.

References

    1. KDIGO Workgroup. KDIGO 2017 Clinical Practice Guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017; 7: 1–59
    1. Cunningham J, Locatelli F, Rodriguez M.. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011; 6: 913–921
    1. Goodman WG, Quarles LD.. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 2008; 74: 276–288
    1. Thomas R, Kanso A, Sedor JR.. Chronic kidney disease and its complications. Prim Care 2008; 35: 329–344
    1. De Boer IH, Gorodetskaya I, Young B. et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762–2769
    1. Levin A, Bakris GL, Molitch M. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31–38
    1. Fliser D, Kollerits B, Neyer U. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600–2608
    1. Gal-Moscovici A, Sprague SM.. Bone health in chronic kidney disease-mineral and bone disease. Adv Chronic Kidney Dis 2007; 14: 27–36
    1. Moe S, Drueke T, Cunningham J. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945–1953
    1. Fishbane S, Shapiro WB, Corry DB. et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3: 1718–1725
    1. Moe SM, Chertow GM, Coburn JW. et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760–771
    1. Wetmore JB, Liu S, Krebill R. et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110–116
    1. Wetmore JB, Quarles LD.. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol 2009; 5: 24–33
    1. Bushinsky DA, Messa P.. Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin D sterols in dialysis patients. NDT Plus 2008; 1: i18–i23
    1. Parikh C, Gutgarts V, Eisenberg E. et al. Vitamin D and clinical outcomes in dialysis. Semin Dial 2015; 28: 604–609
    1. de Francisco AL, Gillespie IA, Gioni I. et al. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. Nefrologia 2016; 36: 164–175
    1. Reams BD, Dluzniewski PJ, Do TP. et al. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective new-user cohort design. BMC Nephrol 2015; 16: 175.
    1. Parsabiv™ (etelcalcetide). Full Prescribing Information. Thousand Oaks, CA: Amgen Inc, 2017
    1. Parsabiv™ (etelcalcetide). Summary of Product Characteristics. Breda, The Netherlands: Amgen Europe B.V, 2017
    1. Alexander ST, Hunter T, Walter S. et al. Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol 2015; 88: 853–865
    1. Ma JN, Owens M, Gustafsson M. et al. Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor. J Pharmacol Exp Ther 2011; 337: 275–284
    1. Block GA, Bushinsky DA, Cunningham J. et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 2017; 317: 146–155
    1. Liss K, Block GA, Chertow GM. et al. Initiation of AMG 416 after discontinuation of cinacalcet. J Am Soc Nephrol 2015; 26: 204A [abstr TH-PO516]
    1. Block GA, Bushinsky DA, Cheng S. et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 2017; 317: 156–164
    1. Block G, Chertow G, Sullivan J. et al. An integrated analysis of safety and tolerability of etelcalcetide in adult patients on hemodialysis with secondary hyperparathyroidism. Presented at: American Society of Nephrology Annual Meeting, New Orleans, LA, USA, 31 October–5 November 2017
    1. Shigematsu T, Fukagawa M, Yokoyama K. et al. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 2018; 22: 426–436
    1. Sensipar® (cinacalcet). Full Prescribing Information. Thousand Oaks, CA: Amgen Inc, 2017
    1. Fielden MR, Dean C Jr, Black K. et al. Nonclinical safety profile of etelcalcetide, a novel peptide calcimimetic for the treatment of secondary hyperparathyroidism. Int J Toxicol 2016; 35: 294–308
    1. Floege J, Tsirtsonis K, Iles J. et al. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int 2018; 93: 1475–1482
    1. Isakova T, Nickolas TL, Denburg M. et al. KDOQI US commentary on the 2017 KDIGO Clinical Practice Guideline Update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2017; 70: 737–751
    1. Block GA, Wheeler DC, Persky MS. et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407–1415
    1. Lim K, Hamano T, Thadhani R.. Vitamin D and calcimimetics in cardiovascular disease. Semin Nephrol 2018; 38: 251–266
    1. Raggi P, Chertow GM, Torres PU. et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327–1339
    1. Block GA, Klassen PS, Lazarus JM. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208–2218
    1. Kroenke MA, Weeraratne D, Deng H. et al. Clinical immunogenicity of the D-amino acid peptide therapeutic etelcalcetide: method development challenges and anti-drug antibody clinical impact assessments. J Immunol Methods 2017; 445: 37–44
    1. Gorovits B, Clements-Egan A, Birchler M. et al. Pre-existing antibody: biotherapeutic modality-based review. AAPS J 2016; 18: 311–320

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel